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 8 
Abstract N-methyl-D-aspartate (NMDA) receptor antagonists are known 9 
to rescue neuronal cell death caused by excessive activation of glutamate 10 
receptors. This phenomenon, known as excitotoxicity, is implicated in the 11 
pathogenesis of several neurodegenerative disorders including ischemia, 12 
Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. 13 
Unfortunately, some antagonists of NMDA receptor have been tested in 14 
clinical trials with discouraging results. However, recent advances in the 15 
physiology and pharmacology of the NMDA receptor have kept the interest 16 
alive to modulate NMDA receptors for therapeutic intervention. 17 
We present here the synthesis of a small library of phenylalalinol-derived 18 
oxazolopyrrolidone lactams and their evaluation as NMDA receptor 19 
antagonists. The compounds were easily synthesized in yields up to 92%. 20 
In addition, one of the compounds has an IC50 of 62 µM and offers 21 
potential to develop more potent NMDA receptor antagonists. 22 
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Introduction 1 
N-Methyl-D-aspartate receptors (NMDAR) are part of the ionotropic 2 
glutamate receptors family. After activation by their co-agonists, glycine 3 
and glutamate, they allow the neural influx of Ca
2+
 through a membrane 4 
ion pore thus playing an important role in the postsynaptic depolarization 5 
[1-4].  6 
Apart of their involvement on synaptic plasticity, which has been 7 
postulated as the neurochemical basis of learning and memory, NMDA 8 
receptors have been implicated in neuronal death [5]. High levels of 9 
glutamate have been found in brain trauma and other neurodegenerative 10 
diseases, so it is thought that NMDA receptors are potential targets for 11 
neuroprotective compounds [6]. In fact, the adamantanes amantadine and 12 
memantine develop their neuroprotective effects through blockade at the 13 
NMDA receptor. Specifically, memantine is authorized in Western 14 
countries and used therapeutically to slow-down the progression of 15 
Alzheimer’s disease [7].  16 
In 2009, some oral active oxazolidine derivatives were described to 17 
act as NMDA antagonists by preventing the binding of the NMDAR 18 
ligands [8]. Based on this information and due to our interest in the 19 
synthesis of oxazolo lactams [9-10] we decided to extend our research to 20 
the synthesis of enantiopure oxazolopyrrolidone lactams using (S)-21 
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phenylalaninol as a chiral inductor. Since the biological activity is greatly 1 
affected by the absolute stereo-outcome of the compounds, a series of (R)-2 
phenylalaninol derivatives was also prepared. 3 
 4 
Results and Discussion 5 
 6 
Synthesis 7 
Recently, our research group has been interested in the synthesis of 8 
phenylalalinol-derived oxazolopyrrolidone lactams to be evaluated as 9 
NMDA receptor antagonists. The first series of compounds was 10 
synthesized by cyclocondensation of (S)-phenylalaninol 1 with oxoacids 11 
2a-e (Scheme 1). In turn, tricyclic lactams 3a-c were prepared from 2-12 
acylbenzoic acid derivatives 2a-c via reflux in toluene under Dean-Stark 13 
conditions (Table 1). Starting from oxoacids 2d-e and using the same 14 
reaction conditions we obtained the bicyclic lactams 3d-e in 72-73% yields 15 
(Table 1). In all cases, only one diastereoisomer product was observed. 16 
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 1 
Scheme 1 2 
 3 
To study the effect of the corresponding enantiomers as antagonists 4 
at the NMDA receptor, lactams 3a’-c’ were also synthesized starting from 5 
(R)-phenylalaninol with 62-85% yields (Scheme 2, Table 1). 6 
 7 
Scheme 2 8 
 9 
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Table 1 Reaction of phenylalaninol enantiomers 1 and 1’ with oxo acids 2. 1 
Aminoalcohol R Reaction time/h Product Yield (%) 
(S)-phenylalaninol H 16 3a 70 
(S)-phenylalaninol Me 16 3b 92 
(S)-phenylalaninol Ph 16 3c 85 
(S)-phenylalaninol Me 48 3d 73 
(S)-phenylalaninol Ph 48 3e 72 
(R)-phenylalaninol H 16 3a’ 71 
(R)-phenylalaninol Me 16 3b’ 85 
(R)-phenylalaninol Ph 16 3c’ 74 
 2 
NMR spectroscopy 3 
The most important features of the 
1
H NMR spectra of these compounds 4 
are the resonances of the H-3, H-2, and CH2Ar protons. The H-3 signal 5 
appears as a multiplet around 4.33–4.48 ppm. The diastereotopic H-2 6 
protons appear as double of doublets around 4.08-4.33 ppm and 3.58-4.07 7 
ppm. The methylene CH2Ar protons appear as double of doublets around 8 
2.94-3.19 ppm and 2.30-2.99 ppm.  9 
Furthermore, in the 
13
C NMR spectra of compounds 3a-c the newly formed 10 
C-9b chiral center appears around 100ppm. This signal moves downfield as 11 
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the electronic demand of the substituent is increased: δ = 90.78 (H); 98.93 1 
(CH3); 101.04 (Ph) ppm. 2 
Compound 3b' underwent NOESY experiments and it was possible to 3 
observe the correlations depicted in figure 1. As expected and accordingly 4 
with published results with very similar compounds [9] synthesized via 5 
ciclocondensation with an enantiopure aminoalcohols, the stereo-outcome 6 
doesn't seem to be affected by the size of the keto-acid R substituent. 7 
 8 
 9 
 10 
 11 
 12 
Figure 1.- NOESY correlations observed for 3b’. 13 
 14 
NMDA receptor antagonist activity 15 
The NMDA receptor activity of the compounds was evaluated by 16 
measuring their ability to inhibit the intracellular calcium increase induced 17 
by NMDA in cultured cerebellar granule neurons. Addition of glutamate or 18 
NMDA (100 µM) in the presence of glycine (10 µM) produced a robust 19 
and stable increase in intracellular calcium that was challenged with 20 
cumulative additions of the compounds to be tested.  21 
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In our assays, memantine (used as a positive control) yielded an IC50 value 1 
in the low micromolar range (1.48 µM). As it is shown on figure 2, only 2 
three out of the eight synthesized compounds showed an inhibitory activity 3 
higher than the 50% of the maximal effect. Specifically, 3c and 3d showed 4 
an IC50 in the high micromolar range (> 250 µM), while 3e showed a 5 
higher potency as a NMDA antagonist, giving an IC50 of 62.0 µM. Related 6 
to compound 3c, which showed an IC50 of 309.7 µM, the enantiomer 3c’ 7 
was inactive, so it seems that the stereochemistry at the 3 position is 8 
important for activity.  9 
More importantly, the phenyl derivative 3e is more potent as NMDA 10 
receptor antagonism than amantadine (92.0 µM). 11 
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Figure 2.- Inhibitory effect of the synthesized compounds and the 13 
adamantanes memantine and amantadine on NMDA-induced intracellular 14 
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calcium increase in cultured cerebellar granule neurons. The compounds 1 
were tested from 0.1 µM up to the highest possible concentration. Data are 2 
the mean of three different experiments, carried out on three different 3 
batches of cultured cells. 4 
 5 
In summary, we have synthesized and fully characterized several 6 
phenylalalinol-derived oxazolopyrrolidone lactams. In addition we describe 7 
here the potential use of lactam 3e as a hit compound to develop NMDA 8 
receptor antagonists. The data now obtained provides a basis for exploring 9 
if related derivatives have enhanced activity. The synthesis and biological 10 
evaluation of more 3e related compounds are in progress. 11 
 12 
Experimental 13 
 14 
Chemistry 15 
All reagents and solvents were obtained from commercial suppliers and 16 
were used without further purification. Melting points were determined 17 
using a Kofler camera Bock monoscope M. The infrared spectra were 18 
collected on a Shimadzu IRAffinity-1 FTIR infrared spectrophotometer. 19 
Low resolution mass spectra (MS) were performed in LCLEM, Faculdade 20 
de Farmácia, Universidade de Lisboa. Merck Silica Gel 60 F254 plates were 21 
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used as analytical TLC; flash column chromatography was performed on 1 
Merck Silica Gel (200-400 mesh). 
1
H and 
13
C NMR spectra were recorded 2 
on a Bruker 400MHz Ultra-Shield. Proton nuclear magnetic resonance 3 
spectra were recorded at 400 MHz. Carbon nuclear magnetic resonance 4 
spectra were recorded at 100 MHz. 
1
H and 
13
C NMR chemical shifts are 5 
expressed in δ (ppm) referenced to the solvent used and the proton coupling 6 
constants J in hertz (Hz). Spectras were assigned using appropriate COSY, 7 
DEPT and HMQC sequences. 8 
 9 
General procedure for the cyclocondensation reaction of (S)-2-10 
amino-3-phenylpropan-1-ol 1 with keto-acids 2a-e: 11 
To a stirred solution of (S)-2-amino-3-phenylpropan-1-ol in boiling 12 
toluene under inert atmosphere and a Dean-Stark apparatus, was added 1,1 13 
eq. of the desired oxo-acid. The mixture was refluxed until total 14 
consumption of the starting aminoalcohol. The solvent was evaporated and 15 
the crude residue was purified by column chromatography using ethyl 16 
acetate/n-hexane as eluent. The solid products were recrystallized in diethyl 17 
ether/n-hexane. 18 
(3S,9bR)-3-benzyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 19 
(3a) 20 
MoChem_Template_Vers 3.2   May 2011    
 11 
Starting from 90 mg of (S)-2-amino-3-phenylpropan-1-ol in 10 mL 1 
of toluene. The obtained residue was purified by column chromatography 2 
(AcOEt: n-hexane 3:7). Recrystallization from diethyl ether/n-hexane 3 
afforded 110 mg (70%) 3a. 
1
H NMR spectra was found to be identical with 4 
the one described in Ref. [11]. 5 
(3S,9bR)-3-benzyl-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol-6 
5(9bH)-one (3b, C18H17NO2) 7 
Starting from 330 mg of (S)-2-amino-3-phenylpropan-1-ol in 30 mL 8 
of toluene. The obtained residue was purified by column chromatography 9 
(AcOEt:n-hexane 3:7) affording 560 mg (92%) of a colorless oil. 3b. 
1
H 10 
NMR (400 MHz, CDCl3): δ = 7.69 (d, J= 7.4 Hz, 1H, H-Ar), 7.54 (m, 1H, 11 
H-Ar); 7.45 (m, 2H, H-Ar); 7.27 (m, 4H, H-Ar); 7.20 (m, 1H, H-Ar); 4.39 12 
(m, 1H, H-3); 4.21 (dd, J = 8.9, 7.4 Hz, 1H, H-2), 4.07 (dd, J = 8.9, 6.5 Hz, 13 
1H, H-2), 3.21 (dd, J = 13.8, 5.8 Hz, 1H, CH2-Ph), 2.95 (dd, J = 13.8, 8.6 14 
Hz, 1H, CH2-Ph), 1.69 (s, 3H, CH3) ppm; 
13
C NMR (100 MHz, CDCl3): δ 15 
= 174.20 (C=O), 147.26 (Cq), 137.27 (Cq), 133.22 (CH-Ar), 131.60 (Cq), 16 
130.16 (CH-Ar), 129.45 (2CH-Ar), 128.59 (2CH-Ar), 126.80 (CH-Ar), 17 
124.33 (CH-Ar), 122.10 (CH-Ar), 98.93 (C-9b), 74.06 (CH2), 56.77 (CH), 18 
40.89 (CH2-Ph), 23.02 (CH3) ppm; IR (NaCl):   = 1715 (C=O) cm
-1
; MS 19 
(ESI, CP 3.0 kV, SP 30V): m/z calc. = 279 [M]
+
, m/z found 280 [M+H]
+
; Rf 20 
(ethyl acetate: n-hexane 1:1) = 0.769. 21 
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(3S,9bR)-3-benzyl-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-1 
5(9bH)-one (3c, C23H19NO2) 2 
Starting from 100 mg of (S)-2-amino-3-phenylpropan-1-ol in 7 mL 3 
of toluene. The obtained residue was purified by column chromatography 4 
(AcOEt:n-hexane 1:9). Recrystallization from diethyl ether/n-hexane 5 
afforded 193 mg (86%) 3c. M.p.: 92-94 °C; 
1
H NMR (400 MHz, CDCl3): δ 6 
= 7.80 – 7.75 (m, 1H, H-Ar), 7.68 – 7.62 (m, 2H, H-Ar), 7.50 – 7.37 (m, 7 
5H, H-Ar), 7.31 – 7.20 (m, 4H, H-Ar), 7.17 – 7.14 (m, 2H, H-Ar), 4.66 – 8 
4.52 (m, 1H, H-3), 4.44 (dd, J = 8.6, 7.5 Hz, 1H, H-2), 3.96 (dd, J = 8.7, 9 
6.6 Hz, 1H, H-2), 3.02 (dd, J = 13.8, 6.8 Hz, 1H, CH2-Ph), 2.51 (dd, J = 10 
13.8, 8.7 Hz, 1H, CH2-Ph). ppm; 
13
C NMR (101 MHz, CDCl3): δ = 174.52 11 
(C=O), 147.27 (Cq), 138.95 (Cq), 137.61 (Cq), 133.41 (CH-Ar), 131.10 12 
(Cq), 130.23 (CH-Ar), 129.11 (2CH-Ar), 128.94 (2CH-Ar), 128.86 (CH-13 
Ar), 128.64 (2CH-Ar), 126.77 (CH-Ar), 125.96 (2CH-Ar), 124.52 (CH-14 
Ar), 123.56 (CH-Ar), 101.04 (C-9b), 75.91 (CH2), 56.80 (CH), 40.54 (CH2-15 
Ph) ppm; IR (KBr):  = 1721 (C=O)  cm
-1 
; MS (ESI, CP 3.0 kV, SP 16 
30V): m/z calc. = 341 [M]
 +
, m/z found = 342 [M+H]
+
; Rf (ethyl acetate: n-17 
hexane 3:7) = 0.607. 18 
(3S,7aR)-3-benzyl-7a-methyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-19 
one (3d) 20 
MoChem_Template_Vers 3.2   May 2011    
 13 
Starting from 100 mg of (S)-2-amino-3-phenylpropan-1-ol in 10 mL 1 
of toluene. The obtained residue was purified by column chromatography 2 
(AcOEt:n-hexane 1:1) affording 111 mg (73%) of a colorless oil. 3d. 
1
H 3 
NMR spectra was found to be identical with the one described in Ref. [12] 4 
(3S,7aS)-3-benzyl-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-5 
one (3e, C19H19NO2) 6 
Starting from 100 mg of (S)-2-amino-3-phenylpropan-1-ol in 10 mL 7 
of toluene. The obtained residue was purified by column chromatography 8 
(AcOEt:n-hexane 3:7). Recrystallization from diethyl ether/n-hexane 9 
afforded 140 mg (72%) 3e. M.p.: 55-56 °C; 
1
H NMR (400 MHz, CDCl3): δ 10 
7.51 (d, J = 7.4 Hz, 2H, H-Ar), 7.44 – 7.38 (m, 3H, H-Ar), 7.28 – 7.21 (m, 11 
3H, H-Ar), 7.08 (d, J = 7.3 Hz, 2H, H-Ar), 4.50 – 4.35 (m, 1H, H-3), 4.13 12 
(t, J = 8.1 Hz, 1H, H-2), 3.65 – 3.49 (m, 1H, H-2), 2.94 (dd, J = 13.7, 6.2 13 
Hz, 1H, CH2-Ph), 2.89 – 2.77 (m, 1H, H-6), 2.63 – 2.45 (m, 2H, H-6 & H-14 
7), 2.35 – 2.18 (m, 2H, CH2-Ph & H-7) ppm; 
13
C NMR (100 MHz, CDCl3): 15 
δ 179.87 (C=O), 142.55 (Cq), 137.26 (Cq), 128.90 (2CH-Ar), 128.70 16 
(2CH-Ar), 128.49 (2CH-Ar), 128.31 (CH-Ar), 126.60 (CH-Ar), 125.07 17 
(2CH-Ar), 102.27 (C-7a), 72.26 (CH2), 56.44 (CH), 39.92 (CH2-Ph), 35.05 18 
(C-7), 32.57 (C-6) ppm; IR (KBr):  = 1721 (C=O) cm
-1
; MS (ESI, CP 3.0 19 
kV, SP 30V): m/z calc. = 293 [M]
 +
, m/z found = 294 [M+H]
+
; Rf (ethyl 20 
acetate: n-hexane 3:7) = 0.313. 21 
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 1 
General procedure for the cyclocondensation reaction of (R)-2-2 
amino-3-phenylpropan-1-ol 1’ with keto-acids 2a-c: 3 
To a stirred solution of (R)-2-amino-3-phenylpropan-1-ol in boiling 4 
toluene under inert atmosphere and a Dean-Stark apparatus, was added 1,1 5 
eq. of the desired oxo-acid. The mixture was refluxed until total 6 
consumption of the starting aminoalcohol. The solvent was evaporated and 7 
the crude residue was purified by column chromatography using ethyl 8 
acetate/n-hexane as eluent.  9 
(3R,9bS)-3-benzyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 10 
(3a’) 11 
Starting from 100 mg of (R)-2-amino-3-phenylpropan-1-ol in 15 mL 12 
of toluene. The obtained residue was purified by column chromatography 13 
(AcOEt:n-hexane 2:8). Recrystallization from diethyl ether/n-hexane 14 
afforded 125 mg (71%) 3a’. 1H NMR spectra was found to be identical 15 
with the one described in Ref. [11]. 16 
(3R,9bS)-3-benzyl-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol-17 
5(9bH)-one (3b’, C18H17NO2) 18 
Starting from 100 mg of (R)-2-amino-3-phenylpropan-1-ol in 15 mL 19 
of toluene. The obtained residue was purified by column chromatography 20 
(AcOEt:n-hexane 2:8) affording 157 mg (85%) of a colorless oil. 
1
H NMR, 21 
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13
C NMR and IR spectra were found to be identical with the ones described 1 
for compound 3b.  2 
(3R,9bS)-3-benzyl-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-3 
5(9bH)-one (3c’, C23H19NO2) 4 
Starting from 100 mg of (R)-2-amino-3-phenylpropan-1-ol in 15 mL 5 
of toluene. The obtained residue was purified by column chromatography 6 
(AcOEt:n-hexane 2:8). Recrystallization from diethyl ether/n-hexane 7 
afforded 167 mg (74%) of 3c’. 1H NMR, 13C NMR and IR spectra were 8 
found to be identical with the ones described for compound 3c. 9 
 10 
NMDA receptor antagonist activity 11 
The activity of the synthesized compounds as NMDA receptor antagonists 12 
was evaluated using primary cultures of rat cerebellar neurons, as described 13 
previously [13]. Briefly, cultures were prepared from 7-8 day-old Wistar 14 
rats (Charles River, France). Cerebella were dissected, minced and 15 
trypsinized, and after several sedimentations, cells were plated on poly-16 
lysinized coverslips placed in 24-well plates at a density of 1•106 cells/mL. 17 
Plates were kept at 37°C in a cell incubator (Heraeus, Germany). After 16-18 
18h, 10 µM cytosine arabinoside (Sigma-Aldrich, USA) was added to 19 
avoid excessive proliferation of astrocytes. Cultures prepared in this 20 
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manner are ready to be used in the NMDA receptor activity assays from the 1 
7th to the 11th day in vitro. 2 
Activity at the NMDA receptor was assessed using the calcium-3 
sensitive probe Fura-2 (Invitrogen, USA). After incubation with 6 µM 4 
Fura-2 acetoxymethyl ester (Fura-2 AM) for 30-45 min at 37°C, a coverslip 5 
was transferred to a plastic holder that was inserted in a quartz cuvette for 6 
fluorescence measurements. Recordings of Fura-2 fluorescence were 7 
performed using a PerkinElmer LS50B luminiscence spectrometer, both at 8 
340 and 380 nm excitation wavelengths, and at 510 nm of emission. The 9 
ratio of F340/F380 (R) is proportional to intracellular calcium. All the 10 
measurements were made at 37°C and under mild stirring. Once the 11 
recording was started, glycine (10 µM) and NMDA (100 µM) were added 12 
to the cuvette, at 50 and 100 s respectively. This produced a sustained 13 
increase in F340/F380, indicating that the NMDA receptors were activated 14 
and that the intracellular calcium concentration was high. This intracellular 15 
calcium increase was challenged with cumulative concentrations of the 16 
compounds under investigation, (from 1•10-7 M up to up to 3•10-4 M). If 17 
the compounds would act as antagonists at the NMDA receptor this would 18 
be detected as a decrease in the value F340/F380. Experiments were 19 
performed in triplicate. Memantine was used as a positive control. 20 
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When a minimum of 50% of inhibition was reached, the IC50 value 1 
was calculated using non-linear regression with GraphPad Prism 5.0. 2 
 3 
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